Genflow Biosciences 正在洽谈将其人类抗衰老疗法应用于宠物，从狗开始，在取得早期成果后。 Genflow Biosciences is in talks to apply its human anti-aging treatments to pets, starting with dogs, after promising early results.

欧洲长寿公司Genflow Biosciences已开始与两家动物保健公司进行秘密会谈,探索如何在宠物,特别是狗身上使用其以人为本的老化治疗方法。 Genflow Biosciences, a European longevity company, has begun confidential talks with two animal health firms to explore using its human-focused aging treatments in pets, particularly dogs. 早期试验显示,这种疗法的开销良好,没有不利影响,预期5个月后将获得正在进行的研究的功效数据。 Early trials show the therapy is well-tolerated with no adverse effects, and efficacy data from ongoing studies are expected in five months. 这种伙伴关系可以提供早期收入,验证平台,扩大市场范围,超越人类治疗方法。 The partnerships could provide early revenue, validate the platform, and expand market reach beyond human therapeutics. 该公司在LSE和OTCQB上市,正在推进其多样化战略,进入日益增长的宠物保健部门。 The company, listed on the LSE and OTCQB, is advancing its strategy to diversify into the growing pet health sector.